



Contents lists available at ScienceDirect

Clinical Nutrition ESPEN

journal homepage: <http://www.clinicalnutritionespen.com>

Original article

Transcobalamin receptor gene polymorphisms and mutation in an elderly population

Andrew McCaddon^{a,*}, Daniel F. Carr^b, Hudson Peter^c, Stuart J. Moat^d,
Edward V. Quadros^e

^a Faculty of Social and Life Sciences, Wrexham Glyndwr University, Wrexham, UK

^b Department of Pharmacology and Therapeutics, University of Liverpool, UK

^c COBALZ Limited, 3 Grove Road, Wrexham, UK

^d School of Medicine and Department of Medical Biochemistry, Cardiff University, UK

^e Department of Medicine, SUNY Downstate Medical Center, Brooklyn, NY, USA



ARTICLE INFO

Article history:

Received 3 November 2022

Accepted 27 April 2023

Keywords:

Vitamin B12

Cobalamin

Transcobalamin

Transcobalamin receptor

Gene

Polymorphisms

CD320

SUMMARY

Background & aims: Cellular uptake of the essential nutrient vitamin B12 (cobalamin) occurs via the transcobalamin receptor (TCbIR/CD320), a ubiquitous membrane receptor. Polymorphisms in the receptor exist, though the effect of such variants across patient populations is unknown.

Methods: We determined CD320 genotype in 377 randomly selected elderly individuals.

Results: Three polymorphisms and a codon deletion were identified in the exon 2 region. Haplotype variants had significantly higher holotranscobalamin (holo-TC) values and a higher holo-TC/total cobalamin ratio. TCbIR haplotype explained 46% of the variability in holo-TC values.

Conclusions: This has significant implications for the clinical utility of the 'combined indicator' of B12 status since it is based on a standard rate of intracellular flux via the TC-Cbl receptor. Modification of the model may be required to account for CD320 haplotype.

© 2023 The Author(s). Published by Elsevier Ltd on behalf of European Society for Clinical Nutrition and Metabolism. This is an open access article under the CC BY license (<http://creativecommons.org/licenses/by/4.0/>).

1. Introduction

Vitamin B₁₂ (cobalamin) is an essential nutrient required for DNA synthesis and fatty acid metabolism [1]. It plays a key role in the maturation of red blood cells and the maintenance of nervous system structure and function. Its biological importance is reflected in the detailed sequence of events concerning its assimilation. Following ingestion, it is released from food and becomes bound to salivary haptocorrin [2]. Pancreatic proteases then degrade haptocorrin in the duodenum releasing free B₁₂, which is subsequently bound to intrinsic factor (IF). After ileal absorption by the IF receptor cubilin, the IF-B₁₂ complex is degraded in lysosomes and B₁₂ is released into the circulation. Here it is associated with two separate blood carriers: haptocorrin and transcobalamin. However, only transcobalamin (TC-Cbl) delivers the vitamin to cells. The final step in its assimilation occurs via cellular uptake of this complex,

which is mediated by the transcobalamin receptor (TCbIR/CD320) [3].

Variants of the CD320 gene locus [19p13] are known to exist. A homozygous single codon deletion (NM_016579.3:c.262_264del-GAG (p.Glu88del) was first reported in 2010 in a new-born infant with methylmalonic acidaemia [4]. Cobalamin was elevated in the index case, suggesting reduced cellular uptake by the receptor. In fact, this variant results in a two-fold decrease in affinity for TC-Cbl. Similarly, in large cohorts of healthy younger and older adults, a heterozygous deletion is significantly associated with increased circulating holo-TC concentration at the genome-wide level [5].

The life-long effects of such a deletion in the elderly population perhaps modify cobalamin homeostasis and could have important clinical relevance. For example, moderately elevated plasma total homocysteine (tHcy), a marker of cobalamin and folate status, is now recognized as a significant modifiable risk factor for dementia, including Alzheimer's disease [6,7]. The relative risk of dementia in elderly people for moderately raised tHcy ranges from 1.15 to 2.5, and it is estimated that almost one-third of dementia cases might be attributable to tHcy [6]. Furthermore, intervention trials show

* Corresponding author. Faculty of Social and Life Sciences, Wrexham Glyndwr University, Wrexham, LL11 2AW, USA.

E-mail address: mccaddon@sky.com (A. McCaddon).

that tHcy-lowering treatment with B vitamins markedly slows brain shrinkage and cognitive decline in elderly individuals with cognitive impairment [8–10]. Moreover, a Bayesian network analysis suggests that cobalamin is the key determinant in this relationship [10,11]. Therefore, we sought to identify common variants of CD320 and determine their effects on cobalamin status in an aging population.

2. Materials and methods

The individuals studied were participants in the Medical Research Council Cognitive Function and Ageing Study (MRC CFAS) cohort (www.cfas.ac.uk). This is a longitudinal multicenter study of community dwelling elderly persons aged 65 years and older living in either their own home or residential accommodation who were randomly selected from population-based registers in six United Kingdom sites [12]. As part of MRC CFAS blood samples were collected in 1997 in accordance with the European Prospective Investigation of Cancer guidelines [13]. A 30-mL sample of blood was collected in EDTA-coated, citrate-coated, or plain bottles, and couriered overnight to a central laboratory prior to separation and storage at -80 °C as separate aliquots of serum, plasma, red cells, and buffy coats. A randomly selected subset of 377 individuals had measures of serum cobalamin, holo-TC, and methylmalonic acid (MMA) determined in 2008 and these were used to investigate the TCblR gene. Genomic DNA from whole blood was analysed by amplicon DNA sequencing of the exon 2 region for all individuals. MMA was measured by Gas Chromatography-Mass Spectrometry and holo-TC by the Axis-Shield active B12 immunoassay which provides a measure of the fraction of TC that is saturated with cobalamin and is available for cellular uptake.

2.1. Statistical considerations

Continuous variables are presented as means with their 95% confidence intervals and discrete variables presented as a percentage. The chi squared test was used for comparisons between discrete variables and the Kruskal Wallis test for comparisons between continuous variables. A linear regression model was used to assess the contribution of age, gender and CD320 haplotype to the variability of serum B12 and holo-TC values. Analysis of genotype data to derive values for i) Hardy–Weinberg equilibrium for each

variant and ii) linkage disequilibrium between variants was undertaken using PLINK software [14].

Ethical statement

At its outset in 1991 the MRC Cognitive Function and Ageing Study (CFAS) was approved locally at all sites. Following the introduction of Multi-centre Research Ethics Committees CFAS applied for both Multi-centre and Local Research Ethics Committee approval at each centre (See <https://www.cfas.ac.uk/files/2015/07/Ethical-approvals-for-CFAS.pdf>). The Research Ethics Committees changed the protocol titles many times over the years but the overall goal and consent to analyse samples remained unchanged.

3. Results

The mean age of subjects was 79 years. 53% were female. Cobalamin deficiency was highly prevalent; 28% had holo-TC < 37 pmol/L and 53% had MMA above the upper reference interval of 0.42 µmol/L. Four polymorphisms within the exon 2 region of the TCblR (CD320) gene were identified: an intron 3 T > G SNP (rs2232780) (MAF = 0.058); a heterozygous GAG deletion causing a glutamic acid deletion at codon 88 (MAF = 0.026); an intron 3 G > A SNP (rs2232781) (MAF < 0.01), and a novel A > G SNP encoding a p. T61A amino acid substitution (MAF < 0.01).

Haplotype analysis of the most common polymorphism (rs2232780 (T > G) and a GAG deletion was undertaken. In 377 individuals the haplotype frequencies were as follows: WT/WT (n = 335), WT/rs2232780 G (n = 22) and rs2232780 G/GAG deletion (n = 20). There was a high level of linkage disequilibrium between rs2232780 and the GAG deletion (D' = 1.0, R² = 0.44). MMA did not differ by haplotype, although variants had significantly higher holo-TC values and a higher holo-TC/Cbl ratio (p < 0.001) (Table 1). In a regression model, age, gender and CD320 haplotype explained 46% of the variability in holo-TC values with CD320 variation accounting for a significant amount of this (p < 0.001) (Table 2).

4. Discussion

We found that TCblR/CD320 polymorphisms exist in an elderly population. We limited our analysis to the exon 2 region and identified that as many as 12% of elderly individuals carry a

Table 1
Demographics and metabolites associated with polymorphisms/deletion in exon 2 region of CD320 gene.

	WT/WT (n = 335)	WT/rs2232780 G (n = 22)	rs2232780 G/GAG del (n = 20)	• Discrete Data – Chi square; Continuous Data – Kruskal Wallis Test Statistic; Probability under H ₀
Age	79 (78.5, 80)	80 (77, 83.5)	79 (76, 82)	0.289; p = 0.87
Sex (% Female) ^a	52	55	70	2.49; p = 0.29
MMA	0.57 (0.53, 0.61)	0.62 (0.37, 0.87)	0.52 (0.31, 0.73)	2.25; p = 0.32
Creatinine	98 (94, 101)	102 (89, 116)	90 (80, 100)	1.16; p = 0.56
Serum Folate	5.5 (5.1, 5.9)	4.1 (3.3, 4.9)	5.1 (3.3, 6.9)	2.86; p = 0.24
Serum B ₁₂	215 (198, 231)	183 (150, 215)	174 (143, 204)	1.60; p = 0.45
Holo-TC	54 (50, 56)	66 (54, 79)	80 (63, 96)	15.57; p = < 0.001
Holo-TC/B₁₂ (%)^a	27 (26, 28)	37 (31, 43)	46 (40, 51)	43.78; p = < 0.001

^a Data: mean (95% ci) or %.

Table 2
Influence of haplotype frequency on B₁₂ and holo-TC.

Variable	R ²	Age	Women	WT/rs2232780 G	rs2232780 G/GAG del
Serum B ₁₂	3%	3.3 (1.1–5.5) P = 0.004	-0.9 (-30.6 – 28.8) P = 0.96	-34.6 (-97.5–28.3) P = 0.28	-40.3 (-106.2–25.7) P = 0.23
Holo-TC	46%	-0.5 (-0.9–-0.2) P = 0.002	6.3 (1.9–10.7) P = 0.005	17.6 (8.3–27) P = 0.001	30.4 (20.5–40.2) P = 0.001

haplotype containing at least one of these polymorphisms. Furthermore, the presence of a polymorphism is associated with proportionately more serum cobalamin bound as holo-TC and, together with age and gender, TCbIR/CD320 haplotype explains 46% of holo-TC's variability.

There is no recognized 'gold standard' for determining B₁₂ status. There are four laboratory biological markers of B₁₂ deficiency: total serum B₁₂, holo-TC, plasma tHcy and MMA. However, each has its limitations [15]. Total serum B₁₂ is most frequently used, but these assays mainly provide a measure of B₁₂ bound to haptocorrin which accounts for about 80% of serum cobalamin and not available for cellular uptake. The assays are also influenced by the presence of interfering substances such as anti-IF antibodies in patients with pernicious anaemia and lack the precision and sensitivity to detect changes in holoTC which accounts for <30% of serum cobalamin [16].

The two 'functional' indicators of B₁₂ status – plasma tHcy and MMA – are based on the rationale that insufficiency of the vitamin impairs the activity of two B₁₂-dependent enzymes, namely methionine synthase and methylmalonic acid Co-A mutase, causing respective accumulation of their substrates. Although these can provide a better insight into an individual's B₁₂ status, the lack of consensus for their cut-off values remains problematic in diagnosing B₁₂ deficiency [15]. Furthermore, tHcy levels also reflect folate status, and MMA levels are influenced by renal function. Both can also be affected by thyroid function status.

An alternative suggestion is to use holo-TC to evaluate B₁₂ status, though it remains uncertain whether this is any better than the measurement of serum B₁₂ itself [17]. However, holo-TC does appear to be unaffected by assay interference from high-titre IF antibody levels [18].

If the results from the above markers of B₁₂ status are ambiguous Fedosov et al. suggest using a 'combined indicator' of B₁₂ status [19]. This is a rigorously derived mathematical model combining all four markers and is adjusted for age and folate status. It yields one of five diagnoses: elevated B₁₂, adequate B₁₂, decreased B₁₂, possibly B₁₂-deficient, and probably B₁₂-deficient. Its main drawbacks are the associated expense and general lack of availability of all these markers within routine clinical practice, though the authors have recently provided a refined model that provides for 'missing markers' [20].

However, our results suggest that holo-TC is perhaps not necessarily a marker of 'true' vitamin B₁₂ status in all patients. In certain individuals, 'high' holo-TC levels might also reflect decreased cellular uptake due to an inherited specific CD320 haplotype. This observation has significant clinical implications for the 'combined indicator' of B₁₂ status, since this model is based on an assumed standard rate of intracellular flux via the TC-Cbl receptor [19,20]. Some modification of the model is likely to be required to account for an individual's known CD320 haplotype. Further larger confirmatory studies are required. It will also be interesting to evaluate the effect of CD320 haplotype on the incidence of disorders associated with B₁₂ insufficiency in the elderly, such as cognitive decline and dementia, including Alzheimer's Disease [21].

Statement of authorship

AM conceived the study, DFC and PH performed statistical analyses, SM determined serum cobalamin, holo-TC and MMA assays and EVQ performed DNA sequencing of TCbIR/CD320. All authors contributed equally to writing the paper.

Funding sources

The MRC CFAS study is funded by the Medical Research Council, UK.

Declaration of competing interest

No author had any conflict of interest to declare.

Acknowledgments

We wish to thank Richard Ellis and members of the MRC CFAS Research Team, in particular Cherie McCracken. *Grants and Funding:* MRC CFAS is funded by the Medical Research Council (MRC).

References

- [1] Green R, Miller JW. Vitamin B12 deficiency. *Vitam Horm* 2022;119:405–39.
- [2] McCorvie TJ, Ferreira D, Yue WW, Froese DS. The complex machinery of human cobalamin metabolism. *XXX-XXX J Inherit Metab Dis* 2023;46. <https://doi.org/10.1002/jimd.12593>.
- [3] Quadros EV, Nakayama Y, Sequeira JM. The protein and the gene encoding the receptor for the cellular uptake of transcobalamin-bound cobalamin. *Blood* 2009;113(1):186–92.
- [4] Quadros EV, Lai SC, Nakayama Y, Sequeira JM, Hannibal L, Wang S, et al. Positive newborn screen for methylmalonic aciduria identifies the first mutation in TCbIR/CD320, the gene for cellular uptake of transcobalamin-bound vitamin B(12). *Hum Mutat* 2010;31(8):924–9.
- [5] Velkova A, Diaz JEL, Pangilinan F, Molloy AM, Mills JL, Shane B, et al. The FUT2 secretor variant p.Trp154Ter influences serum vitamin B12 concentration via holo-haptocorrin, but not holo-transcobalamin, and is associated with haptocorrin glycosylation. *Hum Mol Genet* 2017;26(24):4975–88.
- [6] Smith AD, Refsum H, Bottiglieri T, Fenech M, Hooshmand B, McCaddon A, et al. Homocysteine and dementia: an international consensus statement. *J Alzheimers Dis* 2018;62(2):561–70.
- [7] McCaddon A, Miller JW. Assessing the association between homocysteine and cognition: reflections on Bradford Hill, meta-analyses, and causality. *Nutr Rev* 2015;73(10):723–35.
- [8] Smith AD, Smith SM, de Jager C, Whitbread P, Johnston C, Agacinski G, et al. Homocysteine-lowering by B-vitamins slows the rate of accelerated brain atrophy in mild cognitive impairment: a randomized controlled trial. *PLoS One* 2010;5(9):e12244.
- [9] de Jager CA, Oulhaj A, Jacoby R, Refsum H, Smith AD. Cognitive and clinical outcomes of homocysteine-lowering B-vitamin treatment in mild cognitive impairment: a randomized controlled trial. *IntJGeriatrPsychiatry* 2011;27:592–600.
- [10] Douaud G, Refsum H, de Jager CA, Jacoby R, Nichols TE, Smith SM, et al. Preventing Alzheimer's disease-related gray matter atrophy by B-vitamin treatment. *Proc Natl Acad Sci U S A* 2013;110(23):9523–8.
- [11] Smith AD, Refsum H. Dementia prevention by disease-modification through nutrition. *J Prev Alzheimers Dis* 2017;4(3):138–9.
- [12] Cognitive function and dementia in six areas of England and Wales: the distribution of MMSE and prevalence of GMS organicity level in the MRC CFA study. The medical Research Council cognitive function and ageing study (MRC CFAS). *Psychol Med* 1998;28(2):319–35.
- [13] Riboli E, Kaaks R. The EPIC project: rationale and study design. *European prospective investigation into cancer and nutrition. Int J Epidemiol* 1997;26(Suppl 1):S6–14.
- [14] Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, Bender D, et al. PLINK: a tool set for whole-genome association and population-based linkage analyses. *Am J Hum Genet* 2007;81(3):559–75.
- [15] Sobczynska-Malefora A, Delvin E, McCaddon A, Ahmadi KR, Harrington DJ. Vitamin B(12) status in health and disease: a critical review. *Diagnosis of deficiency and insufficiency - clinical and laboratory pitfalls. Crit Rev Clin Lab Sci* 2021;58(6):399–429.
- [16] Wainwright P, Narayanan S, Cook P. False-normal vitamin B12 results in a patient with pernicious anaemia. *Clin Biochem* 2015;48(18):1366–7.
- [17] Golding PH. Holotranscobalamin (HoloTC, Active-B12) and Herbert's model for the development of vitamin B12 deficiency: a review and alternative hypothesis. *SpringerPlus* 2016;5(1):668.
- [18] MS H, A L J B, Al E. Ability of holotranscobalamin assay (Active B12) to detect severe cobalamin deficiency evidenced by high methylmalonic acid in the presence of high titre intrinsic factor antibody and false normal B12 results. In: 50th Annual Scientific Meeting of the British-Society-for-Haematology Br J Haem. 149; 2010. p. 26.
- [19] Fedosov SN. Metabolic signs of vitamin B(12) deficiency in humans: computational model and its implications for diagnostics. *Metabolism* 2010;59(8):1124–38.
- [20] Fedosov SN, Brito A, Miller JW, Green R, Allen LH. Combined indicator of vitamin B12 status: modification for missing biomarkers and folate status and recommendations for revised cut-points. *Clin Chem Lab Med : CCLM / FESCC*. 2015;53(8):1215–25.
- [21] McCaddon A. Vitamin B12 in neurology and ageing: clinical and genetic aspects. *Biochimie* 2013;95(5):1066–76.